title: Augmentative inhibition of lymphocyte proliferation by cyclosporin A combined with the riminophenazine compounds clofazimine and B669.
abstract: We have investigated the effects of cyclosporin A (CsA, 3-50 ng/ml) in combination with the riminophenazine agents clofazimine and B669 (60-500 ng/ml) on the mitogen- and alloantigen-activated proliferative responses of human mononuclear leukocytes (MNL), as well as on the phospholipase A2 and Na+, K+- adenosine triphosphatase activities of these cells. When used in combination these agents caused inhibition of the proliferative responses of both mitogen- and alloantigen-activated MNL which was at least additive. Combinations of CsA with the riminophenazines also caused augmentative activation of PLA2 and inhibition of Na+, K+-ATPase. The inhibitory effects of these agents, both individually and in combination, on the Na+, K+-ATPase and proliferative responses of MNL were neutralized by the membrane-stabilizing, lysophospholipid complex-forming agent alpha-tocopherol (vitamin E, 20 microgram/ml). These observations suggest that combinations of CsA with riminophenazines cause interactive enhancement of the activity of PLA2 in MNL leading to lysophospholipid-mediated inactivation of Na+, K+-ATPase and consequent inhibition of the proliferative responses of these cells. In the therapeutic setting combinations of these agents may enable reduction in the dose of CsA required to achieve meaningful immunosuppression with a consequent decrease in the risk of chemotherapy-related organ toxicity.
authors.affiliation: Department of Immunology, University of Pretoria, South Africa.
authors.forename: Y
authors.initials: Y
authors.lastname: Prinsloo
authors.forename: C E
authors.initials: CE
authors.lastname: van Rensburg
authors.forename: R
authors.initials: R
authors.lastname: van der Walt
authors.forename: R
authors.initials: R
authors.lastname: Anderson
mesh_terms: D000255:Adenosine Triphosphate / Q000032:analysis; D000328:Adult; D016718:Arachidonic Acid / Q000378:metabolism; D002991:Clofazimine / Q000031:analogs & derivatives* / Q000494:pharmacology*; D016572:Cyclosporine / Q000494:pharmacology*; D004357:Drug Synergism; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D008213:Lymphocyte Activation / Q000187:drug effects*; D008244:Lysophosphatidylcholines / Q000378:metabolism; D000254:Sodium-Potassium-Exchanging ATPase / Q000378:metabolism
chemical_list: D007166:Immunosuppressive Agents; D008244:Lysophosphatidylcholines; D016718:Arachidonic Acid; C030428:B 669; D016572:Cyclosporine; D000255:Adenosine Triphosphate; D002991:Clofazimine; D000254:Sodium-Potassium-Exchanging ATPase